These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33314219)

  • 1. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
    Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ
    J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy.
    Fattahi S; Khalifehzadeh-Esfahani Z; Mohammad-Rezaei M; Mafi S; Jafarinia M
    Immunol Res; 2022 Jun; 70(3):269-275. PubMed ID: 35107743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment.
    Maiese K
    Curr Neurovasc Res; 2020; 17(3):332-337. PubMed ID: 32334502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adapting the Stress Response: Viral Subversion of the mTOR Signaling Pathway.
    Le Sage V; Cinti A; Amorim R; Mouland AJ
    Viruses; 2016 May; 8(6):. PubMed ID: 27231932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.
    Kindrachuk J; Ork B; Hart BJ; Mazur S; Holbrook MR; Frieman MB; Traynor D; Johnson RF; Dyall J; Kuhn JH; Olinger GG; Hensley LE; Jahrling PB
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1088-99. PubMed ID: 25487801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19.
    Mashayekhi-Sardoo H; Hosseinjani H
    J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):17-25. PubMed ID: 34218545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals.
    Fritch EJ; Mordant AL; Gilbert TSK; Wells CI; Yang X; Barker NK; Madden EA; Dinnon KH; Hou YJ; Tse LV; Castillo IN; Sims AC; Moorman NJ; Lakshmanane P; Willson TM; Herring LE; Graves LM; Baric RS
    J Proteome Res; 2023 Oct; 22(10):3159-3177. PubMed ID: 37634194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
    Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells.
    Lau SKP; Wong ACP; Luk HKH; Li KSM; Fung J; He Z; Cheng FKK; Chan TTY; Chu S; Aw-Yong KL; Lau TCK; Fung KSC; Woo PCY
    Emerg Infect Dis; 2020 Dec; 26(12):2961-2965. PubMed ID: 32730733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses.
    Fiorino S; Tateo F; Biase D; Gallo CG; Orlandi PE; Corazza I; Budriesi R; Micucci M; Visani M; Loggi E; Hong W; Pica R; Lari F; Zippi M
    Future Microbiol; 2021 Sep; 16(14):1105-1133. PubMed ID: 34468163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two years into COVID-19 - Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters.
    Greber UF
    FEBS Lett; 2021 Dec; 595(23):2847-2853. PubMed ID: 34787897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
    Pillaiyar T; Laufer S
    J Med Chem; 2022 Jan; 65(2):955-982. PubMed ID: 34081439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Neuronal Invasion and Complications: Potential Mechanisms and Therapeutic Approaches.
    Swain O; Romano SK; Miryala R; Tsai J; Parikh V; Umanah GKE
    J Neurosci; 2021 Jun; 41(25):5338-5349. PubMed ID: 34162747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses.
    Ahn DG; Yoon GY; Lee S; Ku KB; Kim C; Kim KD; Kwon YC; Kim GW; Kim BT; Kim SJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes.
    Shao S; Yang Q; Pan R; Yu X; Chen Y
    Front Endocrinol (Lausanne); 2021; 12():731974. PubMed ID: 34690930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets.
    Kratzel A; Kelly JN; V'kovski P; Portmann J; Brüggemann Y; Todt D; Ebert N; Shrestha N; Plattet P; Staab-Weijnitz CA; von Brunn A; Steinmann E; Dijkman R; Zimmer G; Pfaender S; Thiel V
    PLoS Biol; 2021 Dec; 19(12):e3001490. PubMed ID: 34962926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can We Use mTOR Inhibitors for COVID-19 Therapy?
    Aneva IY; Habtemariam S; Banach M; Sil PC; Sarkar K; Sahebnasagh A; Kamal MA; Khayatkashani M; Kashani HRK
    Comb Chem High Throughput Screen; 2022; 25(11):1805-1808. PubMed ID: 34847842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibition: a double-edged sword in patients with COVID-19?
    Ghasemnejad-Berenji M
    Hum Cell; 2021 Mar; 34(2):698-699. PubMed ID: 33527306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.